Compare Stocks

Date Range: 

 Kala PharmaceuticalsHomology MedicinesVistaGen TherapeuticsMawson Infrastructure GroupKemPharm
SymbolNASDAQ:KALANASDAQ:FIXXNASDAQ:VTGNOTCMKTS:WIZPNASDAQ:KMPH
Price Information
Current Price$3.61$6.48$2.90$0.81$10.81
50-Day Moving Average$5.28$6.78$2.79$0.78$12.08
52-Week Low$3.55$5.94$0.56$0.07$4.54
52-Week High$10.99$16.38$3.55$1.45$22.08
MarketRank™
Overall Score1.51.31.60.61.4
Analysis Score3.43.43.50.02.3
Community Score2.62.52.93.02.9
Dividend Score0.00.00.00.00.0
Ownership Score0.80.81.70.01.7
Earnings & Valuation Score0.60.00.00.00.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyN/ABuy
Consensus Price Target$22.00$24.20$6.50N/A$12.00
% Upside from Price Target509.42% upside273.46% upside124.14% upsideN/A11.01% upside
Trade Information
Market Cap$233.35 million$369.88 million$555.00 million$393.92 million$366.35 million
Beta0.44-0.40.881.583.34
Average Volume2,119,133582,3243,470,238141,517860,690
Sales & Book Value
Annual Revenue$6.36 million$2.70 million$1.09 millionN/A$13.29 million
Price / Sales36.69136.99509.18N/A27.57
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$1.78 per share$4.33 per share$0.51 per share$0.03 per share($14.64) per share
Price / Book2.031.505.69N/A-0.74
Profitability
Net Income$-104,330,000.00$-128,690,000.00$-17,930,000.00$-3,450,000.00$-12,760,000.00
EPS($1.99)($2.80)($0.49)($0.37)($3.00)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/A72.07
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-1,318.03%-300.57%N/AN/A-74.21%
Return on Equity (ROE)-101.43%-49.59%-38.91%N/AN/A
Return on Assets (ROA)-48.93%-38.35%-29.40%-85.32%-1.33%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.66%N/AN/AN/AN/A
Current Ratio8.96%10.76%24.85%1.13%20.70%
Quick Ratio8.55%10.76%24.86%1.13%20.70%
Ownership Information
Institutional Ownership Percentage56.89%50.32%73.89%N/A8.23%
Insider Ownership Percentage34.15%21.70%0.23%N/A1.30%
Miscellaneous
Employees18820511222
Shares Outstanding64.64 million57.08 million191.38 million486.32 million33.89 million
Next Earnings Date8/5/2021 (Estimated)8/9/2021 (Estimated)8/12/2021 (Estimated)N/A8/11/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableNot OptionableOptionable
SourceHeadline
KemPharm Announces U.S. Launch Of Innovative ADHD Treatment Azstarys By CoriumKemPharm Announces U.S. Launch Of Innovative ADHD Treatment Azstarys By Corium
cmlviz.com - July 23 at 1:15 PM
KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc.KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc.
wallstreet-online.de - July 23 at 1:15 PM
KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS(TM) (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc.KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS(TM) (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc.
marketwatch.com - July 23 at 1:15 PM
KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc. - Yahoo FinanceKemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc. - Yahoo Finance
finance.yahoo.com - July 21 at 11:23 PM
Thinking about buying stock in Marathon Digital, Riot Blockchain, KemPharm, Powerbridge Technologies, or LightPath Technologies? - KPVI News 6Thinking about buying stock in Marathon Digital, Riot Blockchain, KemPharm, Powerbridge Technologies, or LightPath Technologies? - KPVI News 6
kpvi.com - July 21 at 6:22 PM
Thinking about buying stock in Marathon Digital, Riot Blockchain, KemPharm, Powerbridge Technologies, or LightPath Technologies? - Salamanca PressThinking about buying stock in Marathon Digital, Riot Blockchain, KemPharm, Powerbridge Technologies, or LightPath Technologies? - Salamanca Press
salamancapress.com - July 21 at 1:22 PM
Should You Sell KemPharm Inc (KMPH) in Biotechnology Industry? - InvestorsObserverShould You Sell KemPharm Inc (KMPH) in Biotechnology Industry? - InvestorsObserver
investorsobserver.com - July 21 at 1:22 PM
KemPharm launches ADHD treatment AZSTARYS in U.S. - Seeking AlphaKemPharm launches ADHD treatment AZSTARYS in U.S. - Seeking Alpha
seekingalpha.com - July 21 at 1:22 PM
KemPharm Announces U.S. Launch of ADHD Treatment AZSTARYS By Corium - BenzingaKemPharm Announces U.S. Launch of ADHD Treatment AZSTARYS By Corium - Benzinga
benzinga.com - July 21 at 8:46 AM
KemPharm Announces US Launch of Innovative ADHD Treatment - GlobeNewswireKemPharm Announces US Launch of Innovative ADHD Treatment - GlobeNewswire
globenewswire.com - July 21 at 8:46 AM
KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc.KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc.
finance.yahoo.com - July 21 at 8:46 AM
Zacks: Brokerages Expect KemPharm, Inc. (NASDAQ:KMPH) Will Post Quarterly Sales of $12.10 MillionZacks: Brokerages Expect KemPharm, Inc. (NASDAQ:KMPH) Will Post Quarterly Sales of $12.10 Million
americanbankingnews.com - July 19 at 5:02 AM
Boom Or Bust: What Are KemPharm Inc.s (NASDAQ:KMPH) Future Prospects? - Marketing SentinelBoom Or Bust: What Are KemPharm Inc.'s (NASDAQ:KMPH) Future Prospects? - Marketing Sentinel
marketingsentinel.com - July 17 at 8:16 AM
KemPharm, Inc. (NASDAQ:KMPH) Expected to Post Earnings of $0.23 Per ShareKemPharm, Inc. (NASDAQ:KMPH) Expected to Post Earnings of $0.23 Per Share
americanbankingnews.com - July 17 at 7:16 AM
InvestorNewsBreaks – KemPharm Inc. (NASDAQ: KMPH) Announces $39M Warrant Exchange Offering - StreetInsider.comInvestorNewsBreaks – KemPharm Inc. (NASDAQ: KMPH) Announces $39M Warrant Exchange Offering - StreetInsider.com
streetinsider.com - July 15 at 6:09 PM
KemPharm, Inc. (NASDAQ:KMPH) CEO Buys $21,645.00 in StockKemPharm, Inc. (NASDAQ:KMPH) CEO Buys $21,645.00 in Stock
americanbankingnews.com - July 15 at 9:08 AM
Comparing KemPharm (NASDAQ:KMPH) & Catalyst Biosciences (NASDAQ:CBIO)Comparing KemPharm (NASDAQ:KMPH) & Catalyst Biosciences (NASDAQ:CBIO)
americanbankingnews.com - July 11 at 7:22 AM
KemPharm, Inc. (NASDAQ:KMPH) is a hot stock at the momentKemPharm, Inc. (NASDAQ:KMPH) is a hot stock at the moment
stocksregister.com - July 10 at 3:10 PM
Is KemPharm Inc (KMPH) Stock at the Top of the Biotechnology Industry? - InvestorsObserverIs KemPharm Inc (KMPH) Stock at the Top of the Biotechnology Industry? - InvestorsObserver
investorsobserver.com - July 6 at 2:48 PM
Comparing Theratechnologies (NASDAQ:THTX) and KemPharm (NASDAQ:KMPH)Comparing Theratechnologies (NASDAQ:THTX) and KemPharm (NASDAQ:KMPH)
americanbankingnews.com - July 5 at 1:06 PM
KEMPHARM, INC : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K) - marketscreener.comKEMPHARM, INC : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K) - marketscreener.com
marketscreener.com - July 2 at 6:05 PM
As The Stock Rises By 14.46% Year-To-Date, KemPharm Inc. (NASDAQ: KMPH)S Stock Continues To Progress In 2021 - Marketing SentinelAs The Stock Rises By 14.46% Year-To-Date, KemPharm Inc. (NASDAQ: KMPH)'S Stock Continues To Progress In 2021 - Marketing Sentinel
marketingsentinel.com - July 1 at 1:23 PM
Costochondritis Treatment Market May See Big Move 2026: KemPharm, GlaxoSmithKline plc, Biovail Corporation, Aurobindo Pharma, Pfizer Inc. – The Manomet Current - The Manomet CurrentCostochondritis Treatment Market May See Big Move 2026: KemPharm, GlaxoSmithKline plc, Biovail Corporation, Aurobindo Pharma, Pfizer Inc. – The Manomet Current - The Manomet Current
manometcurrent.com - June 30 at 12:04 PM
Is KemPharm Inc (KMPH) A Good Stock To Buy? - Yahoo FinanceIs KemPharm Inc (KMPH) A Good Stock To Buy? - Yahoo Finance
finance.yahoo.com - June 29 at 10:54 AM
Is KemPharm Inc (KMPH) A Good Stock To Buy?Is KemPharm Inc (KMPH) A Good Stock To Buy?
finance.yahoo.com - June 29 at 10:54 AM
DateCompanyBrokerageAction
7/7/2021Homology MedicinesChardan Capital
Reiterated Rating
6/4/2021Kala PharmaceuticalsHC Wainwright
Reiterated Rating
5/19/2021VistaGen TherapeuticsRobert W. Baird
Initiated Coverage
5/18/2021Homology MedicinesCanaccord Genuity
Lower Price Target
5/12/2021Kala PharmaceuticalsHC Wainwright
Lower Price Target
5/7/2021Homology MedicinesOppenheimer
Lower Price Target
5/6/2021Kala PharmaceuticalsHC Wainwright
Reiterated Rating
3/10/2021KemPharmHC Wainwright
Reiterated Rating
3/4/2021KemPharmHC Wainwright
Downgrade
3/1/2021Homology MedicinesStifel Nicolaus
Initiated Coverage
2/18/2021VistaGen TherapeuticsJefferies Financial Group
Initiated Coverage
2/17/2021Kala PharmaceuticalsHC Wainwright
Reiterated Rating
1/25/2021KemPharmRoth Capital
Initiated Coverage
1/4/2021VistaGen TherapeuticsWilliam Blair
Upgrade
12/22/2020VistaGen TherapeuticsMaxim Group
Boost Price Target
12/14/2020Homology MedicinesHC Wainwright
Reiterated Rating
11/30/2020Kala PharmaceuticalsNorthland Securities
Reiterated Rating
10/28/2020Kala PharmaceuticalsWedbush
Boost Price Target
10/8/2020VistaGen TherapeuticsAegis
Initiated Coverage
10/5/2020Kala PharmaceuticalsWedbush
Reiterated Rating
9/14/2020Kala PharmaceuticalsJefferies Financial Group
Downgrade
8/18/2020Kala PharmaceuticalsWedbush
Reiterated Rating
8/18/2020KemPharmHC Wainwright
Reiterated Rating
8/11/2020Homology MedicinesOppenheimer
Lower Price Target
8/11/2020Homology MedicinesHC Wainwright
Lower Price Target
8/11/2020VistaGen TherapeuticsMaxim Group
Reiterated Rating
8/10/2020Homology MedicinesChardan Capital
Reiterated Rating
8/7/2020Kala PharmaceuticalsNorthland Securities
Reiterated Rating
8/4/2020Kala PharmaceuticalsWedbush
Reiterated Rating
7/23/2020Kala PharmaceuticalsNorthland Securities
Initiated Coverage
6/26/2020VistaGen TherapeuticsMaxim Group
Reiterated Rating
6/25/2020Homology MedicinesBank of America
Initiated Coverage
6/25/2020Homology MedicinesFIX
Initiated Coverage
6/14/2020Kala PharmaceuticalsWedbush
Reiterated Rating
6/2/2020Kala PharmaceuticalsWedbush
Reiterated Rating
5/31/2020Homology MedicinesChardan Capital
Reiterated Rating
5/29/2020Kala PharmaceuticalsOppenheimer
Initiated Coverage
5/29/2020VistaGen TherapeuticsMaxim Group
Initiated Coverage
5/27/2020Kala PharmaceuticalsJPMorgan Chase & Co.
Boost Price Target
5/27/2020Kala PharmaceuticalsHC Wainwright
Reiterated Rating
5/20/2020KemPharmHC Wainwright
Lower Price Target
5/13/2020Homology MedicinesRoyal Bank of Canada
Initiated Coverage
5/11/2020Kala PharmaceuticalsWedbush
Reiterated Rating
5/8/2020Kala PharmaceuticalsHC Wainwright
Boost Price Target
5/4/2020Kala PharmaceuticalsWedbush
Reiterated Rating
4/29/2020VistaGen TherapeuticsMaxim Group
Initiated Coverage
4/22/2020Kala PharmaceuticalsWedbush
Reiterated Rating
4/13/2020Kala PharmaceuticalsHC Wainwright
Reiterated Rating
3/29/2020Kala PharmaceuticalsWedbush
Reiterated Rating
3/18/2020Kala PharmaceuticalsHC Wainwright
Boost Price Target
3/17/2020Kala PharmaceuticalsWedbush
Reiterated Rating
3/16/2020Homology MedicinesFIX
Upgrade
3/15/2020Homology MedicinesOppenheimer
Upgrade
3/13/2020Homology MedicinesChardan Capital
Reiterated Rating
3/13/2020Homology MedicinesHC Wainwright
Reiterated Rating
3/13/2020Homology MedicinesRobert W. Baird
Boost Price Target
2/24/2020Homology MedicinesChardan Capital
Initiated Coverage
2/6/2020Homology MedicinesHC Wainwright
Reiterated Rating
12/19/2019KemPharmHC Wainwright
Reiterated Rating
12/2/2019VistaGen TherapeuticsChardan Capital
Reiterated Rating
11/20/2019KemPharmHC Wainwright
Reiterated Rating
11/14/2019VistaGen TherapeuticsWilliam Blair
Downgrade
11/3/2019VistaGen TherapeuticsChardan Capital
Reiterated Rating
11/1/2019Homology MedicinesOppenheimer
Initiated Coverage
10/31/2019Homology MedicinesFIX
Initiated Coverage
10/15/2019VistaGen TherapeuticsMaxim Group
Set Price Target
10/9/2019VistaGen TherapeuticsWilliam Blair
Reiterated Rating
10/8/2019VistaGen TherapeuticsMaxim Group
Set Price Target
9/24/2019Homology MedicinesHC Wainwright
Set Price Target
9/9/2019Homology MedicinesRobert W. Baird
Initiated Coverage
9/5/2019KemPharmHC Wainwright
Reiterated Rating
9/5/2019KemPharmRoth Capital
Downgrade
8/28/2019VistaGen TherapeuticsWilliam Blair
Initiated Coverage
7/29/2019VistaGen TherapeuticsChardan Capital
Reiterated Rating
7/26/2019Homology MedicinesCanaccord Genuity
Set Price Target
7/22/2019VistaGen TherapeuticsChardan Capital
Downgrade
6/19/2019KemPharmHC Wainwright
Initiated Coverage
6/11/2019Homology MedicinesHC Wainwright
Set Price Target
5/23/2019KemPharmOppenheimer
Lower Price Target
5/2/2019VistaGen TherapeuticsMaxim Group
Set Price Target
3/6/2019VistaGen TherapeuticsMaxim Group
Reiterated Rating
11/15/2018KemPharmOppenheimer
Set Price Target
11/4/2018VistaGen TherapeuticsOppenheimer
Set Price Target
10/31/2018KemPharmOppenheimer
Set Price Target
10/25/2018VistaGen TherapeuticsMaxim Group
Set Price Target
10/25/2018KemPharmOppenheimer
Set Price Target
10/11/2018KemPharmOppenheimer
Set Price Target
10/3/2018VistaGen TherapeuticsMaxim Group
Set Price Target
9/21/2018KemPharmOppenheimer
Initiated Coverage
9/21/2018KemPharmCIBC
Reiterated Rating
9/20/2018KemPharmOppenheimer
Set Price Target
9/13/2018VistaGen TherapeuticsMaxim Group
Set Price Target
9/5/2018VistaGen TherapeuticsMaxim Group
Set Price Target
8/14/2018KemPharmCanaccord Genuity
Reiterated Rating
8/9/2018KemPharmOppenheimer
Set Price Target
(Data available from 7/23/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.